slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 229,411-229,440
Pages 10,126
Rows per page 30
Component
229,411-229,440 of 303,780
02
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Setup1 hit
04
SAB stands for Scientific Advisory Board.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · SetupLoop · Cost Of Inaction1 hit
05
The slide uses a Gantt-style chart to represent clinical trial progress.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · SetupLoop · Cost Of Inaction1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for therapeutic intervention.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
07
The slide uses a matrix structure to map clinical assets to specific indications and trial names.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
08
The diagram shows the MAPK pathway inhibition. The patient population data is presented as a simple table.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
09
The slide uses a KINOMEscan visualization to show selectivity.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
10
The chart is a classic waterfall plot used in oncology to show best response per patient/model.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
11
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
12
The slide uses a side-by-side comparison of two market segments, each with a big number metric and supporting clinical/regulatory context.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
13
Includes a biological diagram illustrating the RAS protein state transition and mutation impact.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
14
The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
16
Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
17
The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
18
The slide highlights US FDA Fast Track designation and superior PFS performance.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
19
The chart is a mirrored bar chart (diverging bar chart) showing AE frequency by grade.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
20
The slide uses a 2D grid to map dose combinations against regulatory requirements (Project Optimus).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
21
The slide outlines two distinct clinical trial programs (SEACRAFT-1 and SEACRAFT-2) with specific stages, patient cohorts, and regulatory endpoints.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
22
The diagram shows the RAS/MAPK signaling pathway with ERAS-007 targeting ERK.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
23
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
24
The chart is a Kaplan-Meier survival curve comparing a control arm to an experimental arm (EC).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
25
Shows efficacy data for ERAS-007 in combination with Encorafenib and Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
26
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
28
The diagram shows the RAS/MAPK/PI3K signaling pathway. ERAS-801 is shown as an EGFR inhibitor.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
29
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM compared to other indications.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
30
The slide uses a biological diagram to illustrate EGFR mutations in GBM.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
31
The slide uses western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority in mouse models.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
32
The chart is a Kaplan-Meier survival plot comparing three treatment groups.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
33
The diagram illustrates a standard 3+3 or similar dose escalation design leading to an MTD and subsequent safety expansion.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit